All News
Guselkumab in Psoriatic Arthritis
D1 and D2 trials compared guselkumab vs placebo in patients with active PsA, with the major difference between the two being that only biologic-naïve patients were enrolled in the D2 trial. Today, we discuss three abstracts presented at ACR 2021 that expand on that work with an additional year of data.
Read Article
ACR21 Best Abstracts - Day 1
The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.
Read Article
The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis
In rheumatoid arthritis we have a wide range of options available to us when we progress to a biologic treatment option. We have little to differentiate between these agents based on the clinical trials.
Read Article
CARRA STOP-JIA 400pts, Obs study w/ 3 treatments plans :
-Step up
-Early combination
-Biologic first
Which one do you think works best?
I'd say none: overall 40-60% not achieving CDI off steroids at 24 months.
Results: 42% for SU, 52% EC, and 44% BF #Abtr0960 #ACR21 @RheumNow
Aurelie Najm AurelieRheumo ( View Tweet)
Factors associated with Anti Drug Ab against TNFi over 2-y in axSpA pts are:
⭐️ 🔼 Disease activity
⭐️Development of adverse events
⭐️Treatment discontinuation
Abst #0936 #ACR21 @RheumNow
swethaann23 swethaann23 ( View Tweet)
Dr Naovarat reports on 18 year outcomes of HIV and rheumatic disease. 16 patients treated with TNFi, including 2 who switched to tocilizumab and ustekinumab. No major infections. Rising viral load in 1 led to discontinue. Abstr#0965 #ACR21 @RheumNow https://t.co/jcGPaURKmb
Richard Conway RichardPAConway ( View Tweet)
SKIPPAIN results: Spinal pain response after 8 weeks of SEC showed notable differences between HLA-B27 subgroups. Can subtype pre-determine tx efficacy/response? Abs 0917 #ACR21 #RheumNow @RheumNow https://t.co/FKpCqXpobM https://t.co/WbjjyTIaiG
Dr. Rachel Tate uptoTate ( View Tweet)
IV Golimumab efficacy and Early (ED) vs Late (LD) AS
⭐️ED better response than LD with PRO
⭐️Treatment-emergent adverse events/ serious adverse 🔼 LD as compared to ED
Abst #0912 #ACR21 @RheumNow https://t.co/5EaWAvfQ57
swethaann23 swethaann23 ( View Tweet)
French real-world AxSpA cohort analysis showed drug retention of SEC & TNFi were similar. In subgroups analyses, age, BASDAI at dx & BMI were similar. Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/ewtmpxKTNu https://t.co/Yh0nX3x83Z
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 Abst#0836. TCZ switch from IV▶️SC in RA
⭐️11/37 ineffective on SC (30%)
⭐️TCZ IV >8mg/kg, no MTX, h/o ABA failure ass w/ risk of flare on SQ switch
🔥Very relevant w shortages, want more data re: confounders (adherence, disease control)
https://t.co/E9pD4SrXqz @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
Getting closer to personalised medicine in AS, ECM-mediated biomarkers may help predict response to Adalimumab in AS. The biomarkers C1M, C6M and
PRO-C4 were lower in responders to adalimumab treatment after 24 weeks @RheumNow #ACR21 Abst#0915 https://t.co/K2YxPvUAwu https://t.co/w9kcBSFeG9
Dr. Antoni Chan synovialjoints ( View Tweet)
There is increase in ASDAS, BASDAI, CRP and faecal calprotectin levels although not reaching a clinical flare in AS patients who had CZP stopped compared to those who continue CZP full or reduced dose @RheumNow #ACR21 Abst#0916 https://t.co/Wlwirs1QXF https://t.co/jE4smHMXBI
Dr. Antoni Chan synovialjoints ( View Tweet)
Abst0919 #ACR21 @RheumNow Phase III COAST-V 52W (PBO)-controlled study examined the efficacy of IXE in pts with active AS. SF-36 bodily pain, improvements were observed at W16 & W52 whether inflammation was controlled or not per MRI, CRP, MRI+CRP, or BASDAI 5/6. https://t.co/uHLwFctzPr
Olga Petryna DrPetryna ( View Tweet)
Single Intraarticular Canakinumab in Knee OA - 18-week randomized, double-blind, double-dummy Placebo and naproxen-controlled - effect no different than Placebo. Some efficacy in subgroup with high hsCRP. Need for subtypes in OA @rheumnow #ACR21 #abst0728 https://t.co/YlKTMf56wF
Bella Mehta bella_mehta ( View Tweet)
@MilenaGianfran @JYazdanyMD present on differential effects of biologics on CDAI in obese patients with rheumatoid arthritis. Abatacept better than TNFi in obese. Tocilizumab better than TNFi in non-obese. Abstr#0588 #ACR21 @RheumNow #ACRBest https://t.co/UcEpMAmNVw
Richard Conway RichardPAConway ( View Tweet)
French, real-world axSpA cohort analysis shows SEC and TNFi retention rates similar. What do you see in your practice? Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/vu3zUwfktl https://t.co/v6DLjWJMn4
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR21 Abs#0825
Early RA -Rx-naive: 48 wk, csDMARD+GC vs. 3 bDMARD+MTX (CZP/ABA/TCZ)
⭐️Superiority for ABA+MTX and CZP+MTX vs. to csDMARD+GC, not in TCZ+MTX
⭐️ Radiographic progression low in all
▶️ Short study w very aggressive 1st line combo Rx
https://t.co/TJPZkqmN8z @Rheumnow
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Abs#0828. SELECT-COMPARE UPA vs ADA for RA at 3 yrs
⭐️More pts stay on UPA vs ADA (47 vs 36%)
⭐️Adverse drug events similar between groups. UPA has ⬆️ zoster, lymphopenia, hepatic and CPK elevations
https://t.co/eLCytSX7Gz @Rheumnow https://t.co/i8NjSgImVq
Links:
Eric Dein ericdeinmd ( View Tweet)
Interim analysis of real world data on AQUILA (Dr Uta Kiltz et al): how gender affects SEC tx and retention rates:
🔷Improvement in BASDAI, PGA, global fnxn & depressive mood - similar in both ♂️&♀️
🔷High SEC retention rates irrespective of gender
@RheumNow #ACR21 abs909 https://t.co/rXa6ELXDJo
sheila RHEUMarampa ( View Tweet)
Gender differences in secukinumab treatment of AS?
⭐️improved disease activity, global function, depression in men and women
⭐️women ⬆️disease burden
⭐️high retention rates irrespective of gender
Abs#909
#ACR21 @RheumNow
https://t.co/L6mCxuSMo1 https://t.co/pR3OBoXqaT
Robert B Chao, MD doctorRBC ( View Tweet)